welcure-drugs-pharmaceuticals-ltd

Welcure Drugs & Pharmaceuticals Ltd Financials
Company Logo

Welcure Drugs & Pharmaceuticals Ltd Financial Statement

Welcure Drugs & Pharmaceuticals Ltd Income Statement

Quarterly

Annual

*All values are in Rs. Cr

Particulars
Sep 2024
Revenue24.55
Operating Expense22.71
Net Profit1.84
Net Profit Margin7.49
Earning Per Share0.16
EBIDTA1.85
Effective Tax RateTBA

Welcure Drugs & Pharmaceuticals Ltd Profit & Loss

*All values are in Rs. Cr

Standalone

Consolidated

Particulars
Mar 2024
Total Revenue AnnualTBA
Operating Expenses Annual0.23
Operating Profit Annual-0.14
Interest AnnualTBA
Depreciation0.04
Net Profit Annual-0.17
Tax AnnualTBA

Welcure Drugs & Pharmaceuticals Ltd Cash Flow

*All values are in Rs. Cr

Standalone

Consolidated

Particulars
Mar 2024
Cash Flow at the BeginningTBA
Cash Flow from Operations-0.13
Cash Flow from Investing0.17
Cash Flow from Financing-0.02
Cash Flow at the End0.02

Welcure Drugs & Pharmaceuticals Ltd Key Ratios

*All values are in Rs. Cr

Standalone

Consolidated

Particulars
Mar 2024
PBDIT Margin (%)TBA
PBIT Margin (%)TBA
PBT Margin (%)TBA
Net PROFIT Margin (%)TBA
Return On Networth / Equity (%)TBA
Return On Networth /Employed (%)TBA
Return On Assets (%)TBA
Total Debt / Equity (X)TBA
Asset Turnover Ratio (%)TBA

Welcure Drugs & Pharmaceuticals Ltd Balance Sheet

*All values are in Rs. Cr

Standalone

Consolidated

Particulars
Mar 2024
Fixed Assets Annual0.02
Total Current Assets Annual0.03
Non Current Assets Annual1.34
Total Shareholders Funds Annual1.34
Total Assets Annual1.37

Welcure Drugs & Pharmaceuticals Ltd Earning Calls

No Data Availabe

Get Your FAQs Right

As of Dec 11, 2024, Welcure Drugs & Pharmaceuticals Ltd has a market capitalization of 5.08 Cr. Value Research classifies it as a Micro-Cap company.
Yes, Welcure Drugs & Pharmaceuticals Ltd is debt-free with a debt-to-equity ratio of 0.00.
In FY 2023 , Welcure Drugs & Pharmaceuticals Ltd recorded a total revenue of approximately 0 Cr marking a significant milestone in the company's financial performance.
Welcure Drugs & Pharmaceuticals Ltd's Future outlook anticipates robust growth, with forecasted earnings and revenue rising approximately -0.5% and -100.0% annually, respectively..
Welcure Drugs & Pharmaceuticals Ltd's current PE ratio is -28.22.
Welcure Drugs & Pharmaceuticals Ltd's ROCE averaged 6.4% from the FY ending March 2022 to 2024, with a median of 6.7%. It peaked at 25.4% in March 2022, reflecting strong capital efficiency over the period..
Welcure Drugs & Pharmaceuticals Ltd's latest EBIT is Rs. -0.18 Cr, surpassing the average EBIT of Rs. -0.02 Cr over the 5 years..
Open Demat Account
Verify your phone
+91
*By signing up you agree to our terms & conditions